Test Price
2,800 AED✅ Home Collection Available
PALB2 Gene Pancreatic Cancer Susceptibility Genetic Test
Executive Summary & Core Metrics
- ✓99.9% Diagnostic Sensitivity – Next-Generation Sequencing (NGS) identifies all pathogenic PALB2 variants with high precision.
- ✓VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily from 8 AM to 11 PM for whole blood sample collection.
- ✓Post-Test Genetic Counseling – Complimentary telephonic session with a DHA-licensed genetics expert to discuss results and implications.
- ✓Insurance Pre-Authorization Assistance – Contact via WhatsApp at +971 54 548 8731 for direct billing verification.
Test Overview & Methodology
The PALB2 (Partner and Localizer of BRCA2) gene plays a essential role in DNA repair. Pathogenic variants in PALB2 significantly increase the lifetime risk of pancreatic, breast, and ovarian cancers. This genetic test utilizes Next-Generation Sequencing (NGS) to analyze the entire coding region of the PALB2 gene, detecting all classes of mutations including point mutations, insertions, deletions, and copy number variations. The result is a comprehensive assessment of inherited pancreatic cancer susceptibility.
| Feature | Our PALB2 NGS Test | Closest Alternative (Single‑Gene PCR) |
|---|---|---|
| Technology | Next Generation Sequencing (NGS) – full gene analysis | Targeted PCR/ Sanger sequencing – limited known mutations |
| Detection Rate | >99.9% sensitivity for all pathogenic variants | Misses novel or rare variants; ~80% coverage |
| Turnaround Time | 3–4 Weeks (rigorous quality checks) | 2–3 Weeks |
| Report Depth | Includes VUS interpretation, ACMG classification | Only yes/no for common mutations |
| DHA Compliance | Facility License 1143, ISO 9001:2015 | May not be UAE-licensed |
| Price | 2800 AED | ~1500–2200 AED (variable) |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I stress that PALB2 genetic testing is a powerful tool for understanding your inherited cancer risk. A positive result must be interpreted within the context of your complete family history and should guide a proactive surveillance strategy. It is absolutely essential to discuss your results with a qualified genetics professional to make informed decisions about your health and that of your family members.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA ID: 9294403
Advisory: Medication Continuity
Do not discontinue any prescribed medication, including hormonal therapies or chemoprevention agents, without consulting your treating physician. Always seek medical advice before making any adjustments to your treatment plan based on genetic test results.
Exclusion Criteria and Red Flags
- • Individuals unable to provide informed consent, including minors without legally authorized guardian approval.
- • Patients with an active, untreated malignancy where immediate therapeutic decisions take priority over genetic susceptibility testing.
- • Pregnant women without a clear genetic counseling indication and specialist referral.
- ER Red Flag: If you experience sudden jaundice, severe upper abdominal pain, or rapid unintentional weight loss, proceed to the nearest emergency department immediately; do not wait for genetic test results.
Patient FAQ & Clinical Guidance
1. Who should consider this PALB2 genetic test?
Individuals with a personal or family history of pancreatic, breast, or ovarian cancer, especially when multiple first-degree relatives are affected or a known PALB2 variant is present in the family. It is also appropriate for healthy individuals seeking a comprehensive cancer risk assessment under genetic counseling guidance.
2. How is the sample collected, and is it painful?
A DHA-licensed phlebotomist will visit your home or selected location between 8 AM and 11 PM to collect a standard venous whole blood sample. The procedure is quick, virtually painless, and samples are transported using temperature-controlled cold-chain logistics to ensure specimen integrity.
3. What should I expect after receiving my PALB2 result?
You will receive a comprehensive report detailing the specific variant, its classification per ACMG guidelines, and clinical management recommendations. A complementary telephonic genetic counseling session with our genetics expert will be scheduled to help you understand your results and develop a personalized surveillance or prevention plan.
UAE Regulatory & Data Privacy Adherence
This test is performed in full compliance with the United Arab Emirates legal framework:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensures your genetic data is processed and stored with the highest privacy standards.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governs the secure handling of electronic health records and telemedicine.
- Federal Decree-Law No. 4 of 2016 on Medical Liability – establishes the framework for safe clinical practice and informed consent.
Our laboratory operates under DHA Facility License Number: 1143, located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | PALB2 Gene Pancreatic Cancer Susceptibility Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (venous) or FTA Card |
| Methodology Used | Next-Generation Sequencing (NGS), full gene analysis |
| ICD-10-CM Code | Z15.09 |
| LOINC Code | 91787-7 |
| DHA Facility License & Laboratory Address | DNA Labs UAE, DHA License No: 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians